论文部分内容阅读
取本院内分泌科于2012年2月~2013年8月住院诊治的单用胰岛素效果不佳的2型糖尿病患者34例作为研究对象,根据治疗方式不同分为联合加用利拉鲁肽观察组16例及对照组18例,比较两组患者接受治疗后的血糖及体重指数等相关指标差异;结果:观察组患者接受利拉鲁肽治疗后的血糖、体重指数等各项指标均明显优于对照组,且无明显不良反应;结论:对于单用胰岛素效果不佳的2型糖尿病患者,加用利拉鲁肽可以明显控制血糖、显著减少胰岛素用量,从而提高治疗的安全性及患者的依从性。
Take our hospital endocrine department in February 2012 ~ August 2013 inpatient treatment of single poor insulin type 34 patients with type 2 diabetes as the research object, according to different treatment methods were divided into combined plus liraglutide observation group 16 cases and control group of 18 cases, comparing the two groups of patients receiving treatment of blood glucose and body mass index and other related indicators difference; Results: The observation group received liraglutide treatment of blood glucose, body mass index and other indicators were significantly better than Control group, and no significant adverse reactions; Conclusion: For patients with type 2 diabetes who are not single insulin, the addition of liraglutide can significantly control blood glucose, significantly reduce the amount of insulin, thereby enhancing the safety of treatment and patient compliance Sex.